Long-term outcome of patients with urea cycle disorders and the question of neonatal screening

Claude Bachmann1

  • 1Laboratoire Central de Chimie Clinique, Centre Hospitalier Universitaire Vaudois, Bugnon 46, 1011, Lausanne, Switzerland. Claude.Bachmann@chuv.hospvd.ch

Insights

Neonatal screening for urea cycle disorders shows improved survival with newer therapies, but long-term outcomes and neurodevelopmental impact remain similar to older treatments. Early detection is crucial, but its benefits versus parental acceptance are debated.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Urea cycle disorders (UCDs) are genetic conditions affecting ammonia metabolism.
  • Neonatal screening principles raise questions about effective treatments for UCDs.
  • Current treatments aim to manage hyperammonemia and improve patient outcomes.

Purpose of the Study:

  • To compare the long-term survival and neurodevelopmental outcomes of patients with UCDs treated with different therapeutic approaches.
  • To evaluate the effectiveness of neonatal screening for UCDs in preventing irreversible damage.

Main Methods:

  • Retrospective study of 88 patients with UCDs.
  • Comparison of outcomes between protein restriction alone versus therapy with citrulline/arginine and benzoate.
  • Data collected via questionnaires.

Main Results:

  • Newer therapies improved survival in neonatally presenting UCD patients, but with increased rates of neurodevelopmental delay.
  • Long-term outcomes did not significantly differ between the treatment groups.
  • A significant percentage of patients (56-67%) showed symptoms within the first week of life.

Conclusions:

  • Neonatal screening for UCDs may not prevent irreversible damage due to early symptom onset.
  • Early diagnosis and prompt ammonia level determination are critical, especially in sick neonates.
  • Establishing specialized metabolic centers is essential for effective screening, diagnosis, and long-term patient management.
Abstract

Related Concept Videos

Urea Cycle01:23

Urea Cycle

The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Serum Laboratory Studies, Stool Test, Breath Test01:30

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...